Osteoporosis Therapeutics

Published by: Global Industry Analysts

Published: Mar. 1, 2008 - 278 Pages

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation and Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

Bisphosphonates

Hormone Replacement Therapy/Estrogen Replacement Therapy

Estrogens

Estrogens/Progesterones

Calcitonins

Selective Estrogen Receptor Modulators (SERMs)

Other Therapeutics

II. EXECUTIVE SUMMARY

1. Outlook

Regional Market Perspective

United States

Europe

Japan

2. Industry Overview

Osteoporosis Therapeutics: An Evolutionary Scan

“A Sketch of the Present Industry Scenario”

Facts & Figures: The Osteoporosis Primacy

Snapshots

Table 1: Prevalence of Osteoporosis and Osteopenia in Major Markets including US, Germany, Italy, France, UK, Spain and Japan: 2003-2013 (In Millions) (includes corresponding Graph/Chart)

Factors Influencing Demand

Competitive Landscape

Table 2: Worldwide Osteoporosis Market (2006): Percentage Breakdown by Leading Players-Merck, Novartis, Eli Lilly, Procter & Gamble, Wyeth, and Others (includes corresponding Graph/Chart)

Table 3: Worldwide Osteoporosis Market (2005): Dollar Sales of Leading Osteoporosis Drugs-Fosamax, Actonel, Evista, Miacalcic, and Forteo (In US$ Thousands) (includes corresponding Graph/Chart)

Table 4: Leading Osteoporosis Therapies and its Cost per Day

Market Trends and Issues

Can New Treatments Beat the Gold Standard?

Oral Calcitonin Likely to Emerge as Wonder Drug

New Bisphosphonates Challenge Established Brands

Side Effects of HRT Fuel Natural Alternatives Sales

Bone Formation Drugs Augur New Prospects

A Sneak Into Various Options in Antiresorptives, Anabolic Therapeutics

Estrogen Replacement Therapy: Will Dosing Make a Difference?

Is Prevention Always Better Than Cure?

Peptide-Based Osteoporosis Therapy Gaining Ground

Polymorphism- A Potent Diagnostic Marker

Bisphosphonates - The Other Side

Efficacy of Evista Under the Scanner

3. Major Therapeutic Classes: A Global Perspective

ERT Drugs

Ups and Downs in the ERT Market

Outlook

Bisphosphonates

The leading Therapeutic Market

SERMS

Market Overview

Calcitonins

Market Overview

4. Product Overview

The “Silent Thief”

An Introduction to Bone Physiology

How Osteoporosis Steps In

Osteoporosis: Major Types

Primary Osteoporosis

Secondary Osteoporosis

Osteoporosis - The Aftermath

Prevention: The Only Better Way Out

Osteoporosis Therapies: A Cursory Glance

Nondrug Therapy

Drug Therapy

Major Osteoporosis Therapeutic Classes: A Brief Review

Bisphosphonates

Classification of Bisphosphonates

Etidronate

Alendronate

Risedronate

Calcitonin: A Relatively Safer Therapeutic

What It Is

What It Does

Major Types

Salmon Calcitonin

SERM: A Breakthrough

Raloxifene: The First SERM

SERMs: The Positive Angle

SERMs: The Negative Side

Hormone Replacement Therapy/Estrogen Replacement Therapy: The Longstanding Therapeutic

ERT: The Positive Side

The Negative Angle to ERT

Tereparatide: The First Anabolic Agent

Composition

Forteo: A Leading Brand

Major Therapeutic Classes at a Glance

Osteoporosis Therapeutics: A Peek into the Major Brands

New Drugs/Drug Classes in Pipeline

SERMs

Bisphosphonates

Zoledronic Acid:

Pamidronate:

Reclast

Calcitonin

Parathyroid Hormone (PTH)

Denosumab (AMG-162)

Combination Therapy

5. Major Clinical Trials/Findings

End-Stage Therapies (Under Development) for Osteoporosis Prevention/Cure

GSK & NPS Collaborate for Phase II Clinical Study of Calcilytics

Radius Initiates Phase II Trials for BA058

Novartis and Nordic Initiate Phase III Clinical Trial of Oral Salmon Calcitonin

Medivir Initiates First Human Trials for MIV-701

Osteologix Begins Phase II Trial of NB S101

Zelos and Nektar Initiates Phase I Clinical Trial of Ostabolin-C™

Acceleron Initiates Phase I Clinical Trial of ACE-011

Positive Results from Reclast Clinical Trials

6. Product Introductions/Approvals

P&G Receives FDA Approval for New Dosage of Actonel

Takeda Introduces Benet® for Osteoporosis Treatment

Labtec Obtains Approval to Market Hormone Replacement Patch in Europe

Wyeth Obtains Conditional Approval for Osteoporosis Drug from FDA

Merck’s New Dosage of FOSAMAX PLUS D Gains FDA Approval

Japanese Pharma Majors Receive Approval for Generic Osteoporosis Drug

Roche and GlaxoSmithKline Introduce Bonviva

GlaxoSmithKline and Roche Co-Promoted Boniva Receives FDA Approval

Nycomed’s Preotact Recommended for Approval in Europe

Procter & Gamble and Sanofi-Aventis’ Actonel Approved for Male Osteoporosis

Upsher-Smith Laboratories Rolls Out Fortical Nasal Spray

Teva Receives Tentative FDA Approval for Risedronate Sodium Tablets

GlaxoSmithKline and Roche Receive Approval for Bonviva in Switzerland

Roche’s Once-a-month Bisphosphonate Gets FDA Nod

Actonel with Calcium® Obtains FDA Approval

FDA Approves Unigene’s Nasal Calcitonin

Novavax’s ESTRASORB® Clears FDA Hurdle

Menostar™ Secures FDA Approval

Bonviva Gains European Commission Approval

Schering Introduces New Hormone Therapy Products

Eli Lilly Launches Evista in Japan and China

Proteolos Bags EU Approval

Forcaltonin® Secures European Approval

Ministry of Health Labor and Welfare Approves P&G’s Actonel®

Eli Lilly’s Osteoporosis Drug Obtains US Approval

Vivelle Dot 0.025 ERT Patch from Novogyne

Novartis Rolls Out Estradot

Pfizer Launches FemHRT

Ligand Unveils LGD2226

7. Recent Industry Activity

Schering-Plough Acquires Organon BioSciences

Faes Farma Signs Marketing Agreement with Roche and GlaxoSmithKline

Alethia and Emerillon Collaborate on Osteoporosis Therapies

Ipsen Enters into Co-marketing Agreement with MSD

Unigene Enters into Agreement with Novartis

Pharming Group Granted Subsidies to Develop Osteoporosis Drugs

Procter & Gamble Terminates Nasal Spray Collaboration with Nastech Pharmaceutical

Pharming Group Acquires DNage

Amgen Acquires Abgenix

P&G Licenses Osteoporosis Nasal Spray Rights from Nastech

Eli Lilly to Close Basingstoke Plant

Galapagos Acquires Drug Discovery Platform of Discovery Partners

Duravest Acquires Bio-Magnetic Therapy

Galapagos Acquires ProStrakan’s ProSkelia

Roche Inks a Marketing Agreement with Elder Pharma

Chugai and Taisho Sign a Joint Development and Marketing Agreement

Theragenex Signs a Licensing Agreement with Zylera

Radius Acquires Licensing Agreement for Eisai’s SERMs

Alkermes Partners with Eli Lilly to Develop and Market PTH Formulation

Radius Acquires Exclusive Rights to Karo Bio’s SARMS

Unigene Enters into Agreement with Tzamal Bio

Galapagos Acquires Inpharmatica

Bio-Rad Acquires Provalis Medical Diagnostics Operations

Daiichi Sankyo to Market Evista in Europe

Biocon Acquires Nobex

Radius and Ipsen Enters into Licensing Agreement

Novartis Acquires Hexal AG

Nippon Chemiphar Signs Agreement with Velcura Therapeutics

Biopotential Capital Acquires Osta Biopharma

Dnage Commences DNA Research Programme for Osteoporosis Therapeutics

Nastech Initiates Phase I Study of PTH 1-34

SEQUENOM Collaborates with P&G Pharmaceuticals

Novartis Extends Alliance with Emisphere

Eli Lilly Markets Forteo in Europe

Avesthagen Co-develops Osteoporosis Drug with CCBR

Nastech Signs Agreement with Par Pharmaceutical, Inc

Unigene and Novartis in a Licensing and Manufacturing Agreement

8. Developments in the Recent Past

Wyeth Ties Up with Tanox and Galapagos

Galapagos and P&G Collaborate to Develop Osteoporosis Drugs

Unigene Grants License to Faran

Genome Collaborates with Amgen

Unigene Joins Hands with Shijiazhuang

Unigene, GSK Signs License Collaboration

Unigene and Upsher-Smith in a Licensing Agreement

Celgene and Novartis Embark on Joint Research for SERMs

Roche, GSK Signs Global Agreement

Novogyne Procures CombiPatch™ from Aventis

9. Focus on Select Global Players

Eli Lilly and Company (US)

F.Hoffmann-La Roche Ltd (Switzerland)

Merck & Co., Inc. (US)

Novartis AG (Switzerland)

Novo Nordisk A/S (Denmark)

Organon

Procter & Gamble Pharmaceuticals Inc. (US)

Sanofi-Aventis SA (France)

Servier SA (France)

Solvay Pharmaceuticals Inc. (US)

Unigene Laboratories, Inc. (US)

Wyeth (US)

10. Global Market Perspective

Table 5: World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 6: World Long-Term Projections for Osteoporosis Therapeutics by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 7: World 10-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

Table 8: World Recent Past, Current & Future Analysis for Bisphosphonates by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 9: World Long-Term Projections for Bisphosphonates by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 10: World 10-Year Perspective for Bisphosphonates by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

Table 11: World Recent Past, Current & Future Analysis for ERT Drugs by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 12: World Long-Term Projections for ERT Drugs by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 13: World 10-Year Perspective for ERT Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

Table 14: World Recent Past, Current & Future Analysis for SERMs by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 15: World Long-Term Projections for SERMs by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 16: World 10-Year Perspective for SERMs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

Table 17: World Recent Past, Current & Future Analysis for Calcitonins by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 18: World Long-Term Projections for Calcitonins by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 19: World 10-Year Perspective for Calcitonins by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

III. MARKET

1. United States

A. Market Analysis

Industry Overview

Outlook

Osteoporosis in the US: An Insight

Osteoporosis - An Underserved Market?

Statistical Review

Table 20: Incidence of Osteoporosis in the US (2004) (includes corresponding Graph/Chart)

Table 21: Osteoporosis Prevalence in Post-Menopause Women (includes corresponding Graph/Chart)

Table 22: Number of Osteoporosis Patients Undergoing Osteoporosis Therapies (In Thousands) (includes corresponding Graph/Chart)

Osteoporosis Prescription Market

Table 23: US Osteoporosis Prescription Market (2004-2006): Percentage Share of Leading Drugs- Fosamax, Actonel, Evista, Boniva, Forteo and Others (includes corresponding Graph/Chart)

Competitive Scenario

Table 24: Leading Players in the US Osteoporosis Market (2004) - Market Share by Value Sales for Merck, Eli Lilly, Procter & Gamble/ Sanofi-Aventis and Others (includes corresponding Graph/Chart)

Competitive Review by Segment

Bisphosphonates

Table 25: Leading Players in the US Bisphosphonates Market (2004) - Market Share by Value Sales for Merck and Procter & Gamble/ Sanofi-Aventis

Table 26: Leading Players in the US Bisphosphonates Market (2008) - Market Share by Value Sales for Merck, Procter & Gamble/ Sanofi-Aventis, Novartis and Roche/GSK (includes corresponding Graph/Chart)

SERMs

Calcitonins

Patent Expiry Catalog of Major Osteoporosis Drugs

Product Launches/Approvals

Strategic Corporate Developments

Select US Players

B. Market Analytics

Table 27: US Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, Calcitonins and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 28: US Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, Calcitonins and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 29: US 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, Calcitonins and Others for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

2. Japan

A. Market Analysis

Product Launches/Approvals

Strategic Corporate Development

B. Market Analytics

Table 30: Japanese Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 31: Japanese Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 32: Japanese 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

3. Europe

A. Market Analysis

Outlook

Forsteo: The First Anabolic Agent in Europe

European Regulatory Restricts HRT

Calcitonins Embraces New Label

Table 33: European Market for Osteoporosis Therapeutics (2005): Market Share of Leading Players - Novartis, Merck, Wyeth, Novo Nordisk, Organon, Procter & Gamble, Schering, Solvay and Others (includes corresponding Graph/Chart)

Product Launches/Approvals

Strategic Corporate Developments

Select European Players

B. Market Analytics

Table 34: European Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Geographic Region - France, Germany, The UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 35: European Long-Term Projections for Osteoporosis Therapeutics by Geographic Region - France, Germany, The UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 36: European 10-Year Perspective for Osteoporosis Therapeutics by Geographic Regions - Percentage Breakdown of Dollar Sales for France, Germany, The UK, Italy, Spain, and Rest of Europe Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

Table 37: European Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 38: European Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 39: European 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

3a. France

A. Market Analysis

Strategic Corporate Developments

B. Market Analytics

Table 40: French Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 41: French Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 42: French 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

3b. Germany

Market Analysis

Table 43: German Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 44: German Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 45: German 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

3c. The United Kingdom

A. Market Analysis

Osteoporosis Population Forecast in the UK

Osteoporosis Population in the UK: 2004 -2009E

Product Launches

Strategic Corporate Developments

B. Market Analytics

Table 46: UK Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 47: UK Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 48: UK 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

3d. Italy

Market Analysis

Table 49: Italian Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 50: Italian Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 51: Italian 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

3e. Spain

A. Market Analysis

Strategic Corporate Development

B. Market Analytics

Table 52: Spanish Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 53: Spanish Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 54: Spanish 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

3f. Rest of Europe

A. Market Analysis

Outlook

Romania

Strategic Corporate Developments

Select Players in Rest of Europe

B. Market Analytics

Table 55: Rest of Europe Market for Osteoporosis Therapeutics - Recent Past, Current & Future Analysis by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 56: Rest of Europe Long-Term Projections for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 57: Rest of Europe 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

4. Rest of World

A. Market Analysis

Outlook

Prevalence of Osteoporosis in Various Region-At a Glance

Korea

Table 58: Leading Brands in the Korean Osteoporosis Therapeutics Market (2005): Percentage Share Breakdown by Dollar Sales for Fosamax, Atonel, Alend, Maxmarvil, and Others (includes corresponding Graph/Chart)

China

Schering Pharmaceutical Limited (China) - A Major Player

Product Launch

Strategic Corporate Developments

B. Market Analytics

Table 59: Rest of World Market for Osteoporosis Therapeutics - Recent Past, Current & Future Analysis by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 60: Rest of World Long-Term Projections for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 61: Rest of World 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 52 (including Divisions/Subsidiaries - 66 )

Canada 4

Japan 6

Europe 20

France 3

Germany 3

The United Kingdom 3

Italy 2

Spain 1

Rest of Europe 8

Asia-Pacific (Excluding Japan) 5

Middle East 2

Abstract

This report analyzes the worldwide markets for Osteoporosis Therapeutics in Millions of US$. The specific product segments analyzed are Bisphosphonates, ERT Drugs, SERMs, and Calcitonins. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region and product segment for the period of 2000 through 2015. The report profiles 52 companies including many key and niche players worldwide such as Eli Lilly and Company, F.Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Novo Nordisk, Organon, Procter & Gamble Pharmaceuticals, Inc., Sanofi-Aventis SA, Servier SA, Solvay Pharmaceuticals, Inc., Unigene Laboratories, Inc., and Wyeth. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.


Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Titles available via "online download" are not affected by this and are still delivered to your reading room immediately.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.